NICE approves new treatments for hepatitis C
NICE recommends Daklinza (daclatasvir) for use in some patients with the most difficult-to-treat type of chronic hepatitis C.
Bristol-Myers Squibb (BMS) has welcomed the decision by the National Institute for Health and Care Excellence (NICE) to recommend Daklinza (daclatasvir) in England and Wales as a treatment option for adult patients with chronic hepatitis C virus (HCV) infection. A first-in-class oral, once-a-day pill used in combination with other agents and is recommended to treat certain patients with genotypes 1, 3 and 4. Around 214,000 people in the UK are thought to have chronic HCV and approximately 100,000 patients in the UK are thought to have hepatitis C genotype 3, a difficult-to-treat and often aggressive form of chronic HCV.
Commenting on the NICE recommendation, Anna Maria Geretti, Professor of Virology and Infectious Diseases, University of Liverpool, said: “It is a challenge to treat patients with hepatitis C virus infection, including the significant number of patients with genotype 3, whose condition tends to progress rapidly. In the past there have been limited treatment options available and therefore this decision is an important milestone. Daclatasvir in combination with other agents represents a much needed oral treatment regimen that has been shown to cure the infection in the majority of patients, and we have already seen positive results in the real-life setting in patients with advanced disease.”
HCV genotype 3 is associated with accelerated progression to end-stage liver disease, making treatment time critical. Genotype 3 is associated with increased incidence of hepatocellular carcinoma in cirrhotic patients, and more rapid progression to fibrosis compared with other genotypes, leading to increased mortality. Deaths from HCV have nearly quadrupled between 1996 and 2012 in England.
Up until recently treatment options for genotype 3 patients have been limited. Standard of care has been up to 48 weeks of interferon-based therapy which could be associated with a number of debilitating side effects throughout the body. Daclatasvir in combination with other treatments, has been generally well tolerated and has been shown to clear the infection in most of these patients after 12 or 24 weeks of therapy. It is currently one of only two all oral treatment regimens recommended in EU guidelines by The European Association for the Study of the Liver (EASL) for patients with genotype 3.
HCV is usually asymptomatic in the early years, which contributes to the fact that as many as 50% of people living with the disease may be undiagnosed. Furthermore, 60–70% of all those infected will go on to develop chronic liver disease.
In 2012, healthcare costs associated with the condition were estimated at £82.7 million in the UK. A study has found that by 2035 this figure is projected to rise to £115 million, if current treatment levels remain the same.
Johanna Mercier, General Manager of BMS UK & Ireland commented: “Before now hepatitis C patients have had limited treatment options and we are delighted that NICE has taken the decision to recommend daclatasvir-based regimens. BMS and clinicians alike have seen the positive impact this treatment has had among some patients in the UK to date and it is therefore good news that it will now be available to a wider group of people who are in much need of new treatment options.”
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance